JUL 12, 2017: Rapid, Near-patient Genomic Tests for Infectious Disease set to Revolutionize Antibiotic Prescribing and Patient Care
FEB 23 2017: DNAe announces opening of US facility, expansion of operations and launches product brand
DEC 4 2016: DNAe Expands US Operations with Clinical Diagnostic Development and Manufacturing Site in San Diego
MAR 6 2017: DNAe Appoints International Infectious Disease Experts to its Newly Formed Clinical Advisory Board
Breakthrough DNA analysis technology brings patients the benefits of fast and insightful diagnostics.
Diagnostic solutions using fast and powerful genomic analyses.
Analyzing DNA directly on our novel microchip provides rapid and accurate results from a user-friendly system. LiDia can operate in a variety of hospital environments close to the point of need, with flexible levels of throughput to match a wide range of clinical demands.
LiDia launches with a groundbreaking rapid direct-from-specimen test for bloodstream infections that lead to sepsis, followed by a pipeline of tests that provide fast results for serious medical applications such as cancer monitoring.
sepsis - identify the infection faster
Traditional blood culture test
It can take 2 to 6 days to diagnose bloodstream infections using a blood culture. The LiDia™ Bloodstream Infection Test
(BSI) takes approximately 3 hours, directly from an uncultured blood specimen.
Bringing Cutting Edge Technology to the Patient
We have pioneered the use of semiconductor microchips to analyze DNA, leading to simple-to-use systems that produce fast results.
Our innovative application of semiconductor chip technology means LiDia can perform a range of genomic analyses depending on the application – from highly parallel individual tests to powerful next generation sequencing (NGS).
Combating sepsis and the global threat of
Over the last few years there has been a galvanizing of
action, both within the clinical and political communities, to
tackle the alarming rise of antimicrobial resistance (AMR).
Strong focus is being placed on reducing overuse and
misdirected use of antibiotics.
LiDia is uniquely positioned to respond to the growing
threat of AMR. In September 2016, DNAe was awarded up to $51.9M contract by the Biomedical Advanced Research and Development Authority, a division of the Office of the Assistant Secretary for Preparedness and Response in the US Health and Human Services to develop a semiconductor DNA sequencing platform for rapid diagnosis of antimicrobial resistant infections and influenza.
LIDIA IS UNIQUELY POSITIONED
TO RESPOND TO THE THREAT OF
Work with us
AND BEGIN A FASCINATING
JOURNEY OF DISCOVERY
We’re creating something radically different products that change the game for early diagnosis and monitoring of potentially fatal diseases. The work we do at DNAe helps save lives, this is a powerful motivator and a glorious reason to get involved.
DNAe Group Holdings Ltd
Ugli Campus Block C
56 Wood Lane
DNA Electronics, Inc.
1891 Rutherford Road
Carlsbad, CA 92008
+1 (760) 444-9410
KEEP IN TOUCH